RJA
GPCR icon

Raymond James & Associates’s Structure Therapeutics GPCR Stock Holding History

Raymond James & Associates’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,705
Closed -$233K – 3967
2023
Q4 		$233K Buy
+5,705
New +$327K ﹤0.01% 3433

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Raymond James & Associates's GPCR Position: Q1 2024 in Review

Raymond James & Associates sold out of Structure Therapeutics (GPCR) in Q1 2024, closing a stake of 5,705 shares — an estimated $233K sold.

Raymond James & Associates first reported a position in GPCR in Q4 2023 and held it in 1 quarter. The position peaked at $233K in Q4 2023. 119 funds tracked by Wall St. Rank hold GPCR as of Q1 2024.

  • Raymond James & Associates reported no remaining Structure Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Raymond James & Associates sold 5,705 Structure Therapeutics shares in Q1 2024, an estimated $233K.
  • Raymond James & Associates first reported a position in Structure Therapeutics in Q4 2023 and held it in 1 quarter.
  • Raymond James & Associates's Structure Therapeutics position peaked at $233K in Q4 2023.
  • 119 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2024.

Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.